Navigation Links
General Anesthesia For Heroin Detoxification Is No Good

Research studies have shown that use of general anesthesia for heroin detoxification is no better when compared to other methods of detoxification. The study, which came in the latest issue of JAMA, also points out the fact that use // of general anesthesia in these circumstances can also lead to adverse life threatening events.

Medically supervised heroin withdrawal remains plagued by patient discomfort and high dropout rates. Many patients fear the physical discomfort of withdrawal and either avoid treatment or leave it prematurely. Even those who complete the detoxification process have high relapse rates, partly due to the absence of continuing treatment.

These problems have given rise, in the past 15 years, to ultra-rapid, or anesthesia-assisted opioid detoxification, which involves administering an opioid antagonist drug to neutralize the effects of heroin while the patient is unconscious from general anesthesia.

This has been publicized as a fast, painless way to withdraw from heroin. However, this treatment is expensive, not covered by insurance, and lacks good evidence to support efficacy. There are also significant concerns about health risks. The detoxification procedure is usually followed by longer-term treatment with an antagonist drug such as naltrexone to block the effects of any subsequent heroin use.

Researchers from Columbia University, New York, had conducted a randomized controlled trial between 2000 and 2003 to evaluate the safety, tolerability, and efficacy of anesthesia-assisted rapid opioid detoxification compared with two other inpatient withdrawal and naltrexone treatment procedures.

The researchers found that average withdrawal severities were comparable across the 3 treatments. Treatment retention over 12 weeks was low and not significantly different among the three groups. Overall, only 11 percent of patients continued in treatment for 12 weeks and had less than two opioid-posit ive urine tests, indicating a high rate of relapse to heroin use. The anesthesia procedure was associated with 3 potentially life-threatening adverse events: severe pulmonary edema and aspiration pneumonia, diabetic ketoacidosis, and a bipolar mixed state requiring hospitalization.

Researchers feel that the study demonstrates no benefit of anesthesia over a safer, cheaper, and potentially outpatient alternative using buprenorphine as a bridge to naltrexone treatment. Taken together with the results of earlier studies, the findings suggest that general anesthesia for rapid antagonist induction does not currently have a meaningful role to play in the treatment of opioid dependence

Source: Newswise
'"/>




Related medicine news :

1. Bypass Heart Surgery Performed Without General Anesthesia
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. General Practitioners are earning mighty amount?
4. Former IMO President Shows Interest In Winning General Election
5. Severe Paucity of General Practitioners in Australia
6. WHO Director-General passes away on 23rd of May
7. Drug Controller General to Withdraw Drug that Affects Vulture Population
8. IT for General Practitioners
9. Fewer Graduates Choosing General Practice
10. Stroke Rehab Programs Should Be Generalized
11. China Nominates Margaret Chan to Run for WHO Director-Generals Post
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: